Friday, November 20, 2026

From Surgical Haemostasis to Something Much Bigger?

Sometimes a simple material can create extraordinary commercial opportunities.

Take Arista AH, developed by Medafor. A plant-derived polysaccharide technology designed to control surgical bleeding. In 2013, C.R. Bard acquired Medafor in a deal worth US$200 million upfront, with another US$80 million potentially payable against milestones.

Then there’s PerClot, developed by China’s Starch Medical. Another plant-based polysaccharide haemostatic technology. Through its commercial relationship with CryoLife (now Artivion), the product ultimately found its way to Baxter International in a transaction worth up to US$60.8 million in 2021.

Two different companies. Similar underlying material science. Significant commercial outcomes.

So what’s the attraction?

These products use relatively inexpensive plant-derived materials, but their value lies in the technology, intellectual property, regulatory approvals and access to global medical markets. Developing and commercialising them takes time, but the potential rewards are substantial.

Now here’s where things get interesting.

What if you took similar material science principles and applied them to something other than stopping bleeding?

That’s precisely the direction Biotanix Labs is pursuing.

Our Hydrogel Delivery Matrix (HDM) is a plant-based, biodegradable material being developed to deliver therapeutic agents directly to targeted sites within the body.

Rather than haemostasis, we’re focused on localised therapeutic delivery: incorporating agents such as lactoferrin and antibiotics into a matrix designed to degrade naturally and release its payload over time.

Our initial areas of interest include bone surgery, spinal fusion and difficult-to-treat infections, with the potential for applications across multiple medical disciplines.

In other words, we’re looking beyond haemostatic products towards a potentially much broader implantable drug-delivery platform.

Arista and PerClot demonstrated what could be achieved with plant-based biomaterials.

We believe the next opportunity may be considerably bigger.

Biotanix Labs is developing that opportunity and looking for the right investment and strategic partners to help take it forward.

Worth a think, isn’t it?